
    
      Comparison of reductions in MRI inflammation in the sacroiliac joints and spine from week 16
      to 24 in patients who at week 16 are in ASDAS remission (i.e. continue sc. secukinumab 150 mg
      monthly) vs. not in ASDAS remission (i.e. increase sc. secukinumab 300 mg monthly). ASDAS
      remission is defined as ASDAS inactive disease i.e. ASDAS<1.3.
    
  